Efficacy Study of the Effect of Budesonide on Emphysema

AstraZeneca

Status and phase: Completed; Phase 4

Conditions: Chronic Obstructive Pulmonary Disease

Treatments: Drug: Pulmicort (budesonide) Turbuhaler

Study type: Interventional

Funder types: Industry

Identifiers

NCT00232674

AD-004-0001

Details and patient eligibility

About

To assess the effect of up to 4 years treatment with budesonide on progression of emphysema in patients with Chronic Obstructive Lung Disease.

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical Chronic Obstructive Pulmonary Disease diagnosis
• smoker

Exclusion criteria

• No exacerbation within the last 30 days
• no long term use of oral corticosteroids

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind